Nachrichten zur Teva Pharmaceutical Industries Limited Aktie

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today…

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced…

TEVA Pharmaceutical Aktie: Fokus auf Schuldenabbau und strategische Neuausrichtung

Zürich (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse der UBS: Die UBS-Analystin Ashwani Verma hat das Kursziel für die Aktie von TEVA Pharmaceutical Industries…

Kaufalarm bei Teva Pharmaceutical (TEVA): Duvakitug erzielt Fortschritte bei der Behandlung entzündlicher Darmerkrankungen!

Teva Pharmaceutical Industries Ltd. (TEVA) ist ein Pharmaunternehmen mit Hauptsitz in Israel. Der Konzern ist vor allem als größter Generikahersteller…

Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?

Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The…

TEVA Pharmaceutical Aktie: Studienresultate sorgen für gute Stimmung an der Börse

Kulmbach (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse vom Online-Anlegermagazin "Der Aktionär": Michel Doepke von "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)…

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today…

Teva to Present at the Jefferies London Healthcare Conference

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today…

Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript

TEVA earnings call for the period ending September 30, 2024.…

EU-Kommission: Millionenstrafe für Pharmakonzern Teva

BRÜSSEL (dpa-AFX) - Weil der Arzneikonzern Teva aus Sicht der EU-Kommission seine marktbeherrschende Stellung missbraucht…

TEVA Pharmaceutical: Kursziel erhöht

London (www.aktiencheck.de) - Rating-Update: Die Analysten von Barclays bestätigen die Empfehlung für die Aktie von TEVA Pharmaceutical Industries Ltd. (ISIN: US8816242098,…

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of…

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

TEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of…

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of…

Teva to Present at the Bank of America 2024 Global Healthcare Conference

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today…

TEVA Pharmaceutical: Solide Argumente für mehrfache Expansion - Aktienanalyse

New York (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von Jefferies & Co: Jefferies & Co rät in einer aktuellen Aktienanalyse weiterhin zum Kauf…

TEVA Pharmaceutical: Phase-2-Daten von Duvakitug als attraktiver Katalysator für die Aktie - Aktienanalyse

Zürich (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von der UBS: Die Analysten der UBS raten die Aktie von TEVA Pharmaceutical Industries Ltd. (ISIN:…

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today…

Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript

TEVA earnings call for the period ending June 30, 2024.…

Global Consumer Health Market Size To Worth USD 713.92 Billion By 2033 | CAGR Of 7.34%

The Global Consumer Health Market Size was Valued at USD 351.46 Billion in 2023 and the Worldwide Consumer Health Market…

Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board

Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help…

TEVA Pharmaceutical: Attraktive Bewertung - Aktie hochgestuft! Aktienanalyse

New York (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von Argus Research: Jasper Hellweg, Analyst von Argus Research, stuft die ADR-Aktie von TEVA Pharmaceutical…

Global Herpes Treatment Market Size To Worth USD 1.87 Billion By 2033 | CAGR Of 4.28%

The Global Herpes Treatment Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Herpes Treatment Market…

Global Allergy Therapeutics Market Size To Exceed USD 42.5 Billion By 2033 | CAGR Of 6.29%

The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market…

Global Contraceptive Drugs Market Size To Worth USD 40.08 Billion By 2033 | CAGR Of 8.02%

The Global Contraceptive Drugs Market Size was Valued at USD 18.53 Billion in 2023 and the Worldwide Contraceptive Drugs Market…

Global Parkinson’s Disease Treatment Market Size To Worth USD 9.14 Billion By 2033 | CAGR Of 6.41%

The Global Parkinsons Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023 and the Worldwide Parkinsons Disease…

Global Anal Fissure Treatment Market Size To Exceed USD 1986.1 Million By 2033 | CAGR Of 5.51%

The Global Anal Fissure Treatment Market Size was Valued at USD 1161.3 Million in 2023 and the Worldwide Anal Fissure…

Global Lenalidomide Drug Market Size To Worth USD 21.47 Billion By 2033 | CAGR Of 5.69%

The Global Lenalidomide Drug Market Size was Valued at USD 12.34 Billion in 2023 and the Worldwide Lenalidomide Drug Market…

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

Global Prostate Health Market Size To Worth USD 78.03 Billion By 2033 | CAGR Of 9.12%

The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023 and the Worldwide Prostate Health Market…

TEVA Pharmaceutical: Kursziel erhöht

London (www.aktiencheck.de) - Rating-Update: Balaji Prasad, Analyst von Barclays, bestätigt die Empfehlung für die Aktie von TEVA Pharmaceutical Industries Ltd. (ISIN:…

TEVA Pharmaceutical: Neues Kursziel

Charlotte (www.aktiencheck.de) - Rating-Update: BofA Securities stuft die Aktie von TEVA Pharmaceutical Industries Ltd. (ISIN: US8816242098, WKN: 883035, Ticker-Symbol: TEV, NYSE-Symbol:…

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)…

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva…

TEVA Pharmaceutical: Neues Kursziel - Aktienanalyse

Minneapolis (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von Piper Sandler: Piper Sandler erhöht in einer aktuellen Aktienanalyse das Kursziel für die Aktie von…

Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript

TEVA earnings call for the period ending March 31, 2024.…

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a…

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE…

Global Pregabalin Market Size To Worth USD 2.18 Billion By 2033 | CAGR of 2.82%

The Global Pregabalin Market Size was Valued at USD 1.65 Billion in 2023 and the Worldwide Pregabalin Market Size is…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Teva Pharmaceutical Industries: Potential Outweighs Concerns

…

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced…

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a…

dpa-AFX ProFeed